Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells
- PMID: 24446827
- DOI: 10.3109/10408363.2013.874403
Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells
Abstract
Protein tyrosine kinases (PTKs) are enzymes that transfer phosphate groups to tyrosine residues on protein substrates. Phosphorylation of proteins causes changes in their function and/or enzymatic activity resulting in specific biological responses. There are two classes of PTKs: the transmembrane receptor PTKs and the cytoplasmic non-receptor PTKs (NRTKs). NRTKs are involved in transduction of signals originating from extracellular clues, which often interact with transmembrane receptors. Thus, they are important components of signaling pathways which regulate fundamental cellular functions such as cell differentiation, apoptosis, survival, and proliferation. The activity of NRTKs is tightly regulated, and de-regulation and/or overexpression of NRTKs has been implicated in malignant transformation and carcinogenesis. Research on NRTKs has shed light on the mechanisms of a number of cellular processes including those involved in carcinogenesis. Not surprisingly, several tyrosine kinase inhibitors are in use as treatment for a number of malignancies, and more are under investigation. This review deals with the structure, function, and signaling pathways of nine main families of NRTKs in normal and cancer cells.
Keywords: Cancer; leukemia; non-receptor tyrosine kinases; signal transduction.
Similar articles
-
Protein tyrosine kinase structure and function.Annu Rev Biochem. 2000;69:373-98. doi: 10.1146/annurev.biochem.69.1.373. Annu Rev Biochem. 2000. PMID: 10966463 Review.
-
Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.Mol Cancer. 2018 Feb 19;17(1):31. doi: 10.1186/s12943-018-0788-y. Mol Cancer. 2018. PMID: 29455667 Free PMC article. Review.
-
Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.J Drug Target. 2016;24(3):192-211. doi: 10.3109/1061186X.2015.1068319. Epub 2015 Jul 27. J Drug Target. 2016. PMID: 26211367 Review.
-
Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance.Cancers (Basel). 2024 Aug 2;16(15):2754. doi: 10.3390/cancers16152754. Cancers (Basel). 2024. PMID: 39123481 Free PMC article. Review.
-
Protein tyrosine kinase-mediated pathways in G protein-coupled receptor signaling.Cell Biochem Biophys. 1999;30(3):369-87. doi: 10.1007/BF02738120. Cell Biochem Biophys. 1999. PMID: 10403057 Review.
Cited by
-
Anchor-based classification and type-C inhibitors for tyrosine kinases.Sci Rep. 2015 Jun 16;5:10938. doi: 10.1038/srep10938. Sci Rep. 2015. PMID: 26077136 Free PMC article.
-
ZAP70 Activation Compensates for Loss of Class IA PI3K Isoforms Through Activation of the JAK-STAT3 Pathway.Cancer Diagn Progn. 2022 May 3;2(3):391-404. doi: 10.21873/cdp.10122. eCollection 2022 May-Jun. Cancer Diagn Progn. 2022. PMID: 35530641 Free PMC article.
-
Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.Blood. 2016 Sep 1;128(9):1234-45. doi: 10.1182/blood-2016-03-707141. Epub 2016 Jun 13. Blood. 2016. PMID: 27297792 Free PMC article. Clinical Trial.
-
c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow.J Clin Invest. 2019 Mar 1;129(3):1167-1179. doi: 10.1172/JCI122440. Epub 2019 Feb 11. J Clin Invest. 2019. PMID: 30629551 Free PMC article.
-
Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy.Pharmaceutics. 2022 Dec 3;14(12):2706. doi: 10.3390/pharmaceutics14122706. Pharmaceutics. 2022. PMID: 36559200 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources